Dapagliflozin Must Be Held for At Least 3 Days Before Surgery
Dapagliflozin should be withheld for at least 3 days (≥72 hours) prior to scheduled surgery to prevent perioperative euglycemic diabetic ketoacidosis, a potentially life-threatening complication. 1, 2, 3
Primary Recommendation
The FDA-approved prescribing information explicitly states: "Withhold DAPAGLIFLOZIN TABLETS for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting." 3
Multiple major guideline organizations provide concordant Class 1 (strong) recommendations for this 3-day minimum discontinuation period, including the American Heart Association, American College of Cardiology, and American Diabetes Association 1, 2, 4, 5
The 3-day minimum applies specifically to dapagliflozin, canagliflozin, and empagliflozin, while ertugliflozin requires a longer 4-day discontinuation period 1, 2, 4
Why 3 Days Is Critical
The primary concern is prevention of euglycemic diabetic ketoacidosis (euDKA), where patients develop life-threatening metabolic acidosis despite normal or near-normal blood glucose levels (<250 mg/dL). 4, 6, 5
SGLT2 inhibitors alter the insulin-to-glucagon ratio, creating a hormonal environment that promotes ketogenesis even when glucose remains normal, and surgical stress amplifies this effect 6
Patients taking SGLT2 inhibitors have a 48% higher risk of perioperative DKA compared to those not taking them (1.02 vs 0.69 per 1000 patients; OR 1.48,95% CI 1.02-2.15) 4
The pharmacologic effects of SGLT2 inhibitors persist beyond their plasma half-life, with clinical effects continuing for 3-4 days after discontinuation, which is why the 3-day minimum is necessary. 6
Critical Clinical Pitfalls
EuDKA can occur even when patients have discontinued dapagliflozin for >72 hours, as demonstrated in case reports showing recurrent ketoacidosis 8 days after the last dose. 4, 7
Do not confuse the 24-hour hold recommendation from older literature with current evidence-based guidelines—multiple case reports document euDKA occurring despite 24-48 hour discontinuation periods. 8, 9
EuDKA presents with high anion gap metabolic acidosis (pH <7.3), decreased serum bicarbonate (<18 mEq/L), and elevated ketones despite relatively normal glucose levels, making it easily missed if clinicians only monitor glucose 6
Non-diabetic patients taking dapagliflozin for heart failure or chronic kidney disease are also at risk for euDKA, challenging the assumption that adequate endogenous insulin prevents ketosis 4, 6
Special Considerations
Emergency surgery carries substantially higher risk than elective procedures (1.1% vs 0.17% ketoacidosis incidence), but the 3-day discontinuation recommendation remains the target when feasible. 4, 6
For patients with heart failure taking dapagliflozin for guideline-directed medical therapy, the metabolic acidosis risk outweighs concerns about temporary interruption—do not continue through surgery 4, 5
The 3-day minimum applies regardless of renal function status, as the primary concern is metabolic acidosis risk rather than drug clearance alone 5
Perioperative Risk Mitigation
Maintain adequate hydration and avoid prolonged fasting periods during the discontinuation window to reduce ketogenesis risk 4, 6
Consider glucose-containing IV fluids if prolonged fasting is unavoidable to mitigate ketone generation 4, 6
Monitor for signs of euDKA (nausea, vomiting, abdominal pain, general weakness) even with normal glucose readings 4
Check capillary ketones and ensure levels are <0.6 mmol/L before restarting dapagliflozin postoperatively 6
When to Resume Dapagliflozin
Resume dapagliflozin only when the patient is clinically stable, eating and drinking normally, and has resumed oral intake (usually 24-48 hours after surgery) 4, 3
Verify capillary ketones are <0.6 mmol/L before reinitiation 6
Provide written sick-day rules to patients at discharge, including information on DKA symptoms and risk-reduction strategies 6